Literature DB >> 17009404

Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy.

R N Zárate1, F Arias, E Bandres, E Cubedo, R Malumbres, J García-Foncillas.   

Abstract

AIM: To evaluate the potential association of xeroderma pigmentosum group D (XPD) codon 751 variant with outcome after chemo-radiotherapy in patients with resected gastric cancer.
METHODS: We used PCR-RFLP to evaluate the genetic XPD Lys751Gln polymorphisms in 44 patients with stage III (48%) and IV (20%) gastric cancer treated with surgery following radiation therapy plus 5-fluorouracil/leucovorin based chemotherapy.
RESULTS: Statistical analysis showed that 75% (12 of 16) of relapse patients showed Lys/Lys genotype more frequently (P = 0.042). The Lys polymorphism was an independent predictor of high-risk relapse-free survival from Cox analysis (HR: 3.07, 95% CI: 1.07-8.78, P = 0.036) and Kaplan-Meir test (P = 0.027, log-rank test).
CONCLUSION: XPD Lys751Gln polymorphism may be an important marker in the prediction of clinical outcome to chemo-radiotherapy in resected gastric cancer patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17009404      PMCID: PMC4124413          DOI: 10.3748/wjg.v12.i37.6032

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  21 in total

1.  A phylogenomic study of DNA repair genes, proteins, and processes.

Authors:  J A Eisen; P C Hanawalt
Journal:  Mutat Res       Date:  1999-12-07       Impact factor: 2.433

2.  Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells.

Authors:  E J Duell; J K Wiencke; T J Cheng; A Varkonyi; Z F Zuo; T D Ashok; E J Mark; J C Wain; D C Christiani; K T Kelsey
Journal:  Carcinogenesis       Date:  2000-05       Impact factor: 4.944

3.  XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects.

Authors:  G Matullo; D Palli; M Peluso; S Guarrera; S Carturan; E Celentano; V Krogh; A Munnia; R Tumino; S Polidoro; A Piazza; P Vineis
Journal:  Carcinogenesis       Date:  2001-09       Impact factor: 4.944

4.  DNA adduct levels and DNA repair polymorphisms in traffic-exposed workers and a general population sample.

Authors:  D Palli; A Russo; G Masala; C Saieva; S Guarrera; S Carturan; A Munnia; G Matullo; M Peluso
Journal:  Int J Cancer       Date:  2001-10-01       Impact factor: 7.396

5.  Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes.

Authors:  Yawei Qiao; Margaret R Spitz; Zhaozheng Guo; Mohammad Hadeyati; Lawrence Grossman; Kenneth H Kraemer; Qingyi Wei
Journal:  Mutat Res       Date:  2002-11-30       Impact factor: 2.433

Review 6.  Genetic variability in susceptibility and response to toxicants.

Authors:  M C Miller; H W Mohrenweiser; D A Bell
Journal:  Toxicol Lett       Date:  2001-03-31       Impact factor: 4.372

7.  Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients.

Authors:  M R Spitz; X Wu; Y Wang; L E Wang; S Shete; C I Amos; Z Guo; L Lei; H Mohrenweiser; Q Wei
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

8.  Polymorphisms of DNA repair genes and risk of non-small cell lung cancer.

Authors:  Shanbeh Zienolddiny; Daniele Campa; Helge Lind; David Ryberg; Vidar Skaug; Lodve Stangeland; David H Phillips; Federico Canzian; Aage Haugen
Journal:  Carcinogenesis       Date:  2005-09-29       Impact factor: 4.944

9.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

Authors:  J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

Review 10.  Adjuvant therapy for gastric cancer.

Authors:  John S Macdonald
Journal:  Semin Oncol       Date:  2003-08       Impact factor: 4.929

View more
  4 in total

1.  DNA repair enzyme polymorphisms and oxidative stress in a Turkish population with gastric carcinoma.

Authors:  Ayse Basak Engin; Bensu Karahalil; Atilla Engin; Ali Esat Karakaya
Journal:  Mol Biol Rep       Date:  2011-03-09       Impact factor: 2.316

Review 2.  Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy.

Authors:  Lucy Gossage; Srinivasan Madhusudan
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

3.  ERCC1 and ERCC2 variants predict survival in gastric cancer patients.

Authors:  Yangkai Li; Zhensheng Liu; Hongliang Liu; Li-E Wang; Dongfeng Tan; Jaffer A Ajani; Qing-Yi Wei
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

Review 4.  Indirect comparison showed survival benefit from adjuvant chemoradiotherapy in completely resected gastric cancer with d2 lymphadenectomy.

Authors:  Qiong Yang; Ying Wei; Yan-Xian Chen; Si-Wei Zhou; Zhi-Min Jiang; De-Rong Xie
Journal:  Gastroenterol Res Pract       Date:  2013-10-01       Impact factor: 2.260

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.